



PROJECTED INCOME AND PROFITS WITH THE IPS OSTEOARTHRITIS TREATMENT SYSTEM

Revenue Generated: Diagnostics & Office Visits, Series of 5 Injections, & DME

The Advanced Arthritis Relief Protocol™ consists of fluoroscopic guided injections of Hyaluronic Acid, a home care physical therapy device, and the *IPS OAide 3000™* unloading knee brace. An estimated breakdown of a typical bilateral course of care is outlined below. Reimbursement figures based upon Medicare global, non-facility, national payment amount. Local Medicare fee schedule available upon request.

Initial Examination and X-Ray	\$266
Initial Arthrogram with Report	\$702
Fluoroscopic Guided HA Injections	\$6,334
Physical Therapy (Home Use Device)	\$2,007
Unloading Knee Brace	\$1,857
Suspension Sleeve (addition to knee brace)	\$243
Total Average Case Fee	\$11,409
Case Value Floor – (80/20) Medicare Allowable	\$9,127

These figures are based upon Medicare’s allowable fee schedule and do not account for secondary insurance payments, major medical policies, or any other third-party payment possibilities. As such these estimates are highly conservative and grossly underestimate the true earning potential of the business model.

Using these conservative figures and operating under the assumption that our average client generates 20 or more cases monthly using our marketing materials...

Your Clinic could generate \$2,190,480 of additional gross collections per year!

Ancillary revenue sources generated from in-office physical therapy, additional diagnostic and therapeutic services, or additional DME (such as EMS devices, etc.), and cross-conversion of OA patients for other medical services such as pain management, chiropractic, primary care, etc. are not factored into the above figures, but may enhance the profitability and case averages of your practice.

*The projected pro forma returns on investment are intended for the purpose of illustrative projections to facilitate analysis and are not guaranteed by Integrative Practice Solutions, LLC. or its affiliates and subsidiaries. Past performance is not an indicator of future results. All investments, including capital equipment purchases, are speculative in nature and involves substantial risk of loss.